Neurobehavioral Profiles and Clinical Consequences of MYT1L-Related Neurodevelopmental Disorder: Insights from the Brain Gene Registry.
Jorge Luis GranadilloiD, Levi KasteriD, Virginia LanzottiiD, Daleep Grewal, Allyson Schreiber, Anna M. AbbacchiiD, Christina A. GurnettiD, Kristen L. KrolliD, Dustin BaldridgeiD, Heather C. HazlettiD, Leann Smith DaWaltiD, John Nicholas ConstantinoiD, Aditi GuptaiD, Joseph D. DoughertyiD
Abstract
MYT1L-Related Neurodevelopmental Disorder (MYT1L-NDD) is a rare autosomal dominant syndrome characterized by intellectual disability, global developmental delay, autism, and obesity. Despite growing recognition, prospective and systematic clinical phenotyping remains limited. Here, we analyzed data from 20 individuals with MYT1L variants enrolled in the Brain Gene Registry (BGR), a national platform integrating genetic, neurobehavioral, and clinical data. Neurobehavioral assessments were conducted using the Rapid Neurobehavioral Assessment Protocol (RNAP), including virtual adaptations of the Shipley, Developmental Profile-4, ASEBA Child Behavior Checklist, and Vineland-3. Diagnostic and medication data were extracted from structured electronic health records (EHR). MYT1L participants were compared to the broader BGR cohort. Fourteen participants had pathogenic or likely pathogenic MYT1L variants. Individuals with confirmed MYT1L-NDD exhibited significant impairments in nonverbal cognition and adaptive functioning, particularly in motor tasks, communication, and daily living skills. Behavioral assessments revealed elevated rates of ADHD symptoms, behavioral conduct problems, oppositional defiance, and anxiety. EHR data showed frequent diagnoses of developmental delays, speech and language disorders, gastrointestinal problems, and obesity. Medication data indicated common prescription of alpha-2 adrenergic agonists and laxatives. This study provides the first prospective, multi-source characterization of MYT1L-NDD. Findings expand our understanding of MYT1L-NDD phenotypes in a quantitative and systematic manner and underscore the value of registry-based approaches for understanding rare neurodevelopmental disorders. Larger, longitudinal studies are needed to further define MYT1L-NDD natural history and inform clinical care.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 8.01
- Field percentile
- top 5%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Expanding the genotype and phenotype spectrum of SYT1-associated neurodevelopmental disorder
Holly Melland, Fabian Bumbak, … Kate Baker·Genetics in MedicinePeer-reviewed·Jan 28, 2022
- Age-Related Characteristics of SYT1-Associated Neurodevelopmental Disorder
Sam G. Norwitz, Josefine Eck, … Kate Baker·Annals of Clinical and Translational NeurologyPeer-reviewed·Dec 2, 2025
- A MYT1L Syndrome mouse model recapitulates patient phenotypes and reveals altered brain development due to disrupted neuronal maturation
Jiayang Chen, Mary E. Lambo, … Joseph D. Dougherty·NeuronPeer-reviewed·Oct 5, 2021
- Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome
Marjolein J.A. Weerts, Kristina Lanko, … Tahsin Stefan Barakat·Genetics in MedicinePeer-reviewed·Aug 3, 2021
- A survey of hypothalamic phenotypes identifies molecular and behavioral consequences of MYT1L haploinsufficiency in male and female mice.
Susan E. Maloney, Katherine B. McCullough, … Joseph D. Dougherty·Hormones and BehaviorPeer-reviewed·Jul 28, 2025
- Neuroanatomical Features of NAA10- and NAA15-Related Neurodevelopmental Syndromes
Rahi Patel, Rikhil Makwana, … Matthew T. Whitehead·Journal of NeuroradiologyPeer-reviewed·Apr 8, 2025